EUVIMEDOpdag EUVIMED
LeserbriefKommentarOpen access · CC BY-NC-ND 4.0

Comment on: Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane

Annelies M C Mavinkurve-Groothuis iD, Esmee C de Baat iD, Elizabeth A M Feijen iD, Leontien C M Kremer, Saro H Armenian iD, Renee L Mulder, Elvira C van Dalen

Pediatric Blood & Cancer · 2023

DOI: 10.1002/pbc.30604 ↗

At a glance

Leserbrief in Pediatric Blood & Cancer, 2023. Written by Annelies M C Mavinkurve-Groothuis and 6 co-authors. Institution: Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands. Major MEDLINE topics: Dexrazoxane, Neoplasms, Polyketides, Razoxane. Cited 2 times so far (Crossref); 4 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

We have read the manuscript “Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane” with great interest.1 Bertorello et al.1 nicely describe the use of anthracyclines and the risk factors of developing anthracycline-related cardiotoxicity in children with cancer. They also mention interventions to mitigate the anthracycline-related cardiotoxicity, with the use of dexrazoxane as primary cardioprotection as one of the important options. The authors conclude with the statement that they support “the use of dexrazoxane in paediatric patients prior to every anthracycline dose.” We fully agree with the authors that it is very important to consider the use of dexrazoxane in children with cancer treated with anthracyclines. However, we do not agree that dexrazoxane should be given prior to every anthracycline dose. In a recently published Cochrane systematic review,2 we presented the evidence on the use of dexrazoxane. We showed that dexrazoxane was effective in preventing or reducing cardiotoxicity, without compromising the antitumor efficacy of anthracyclines. However, it is also important to note that in children dexrazoxane may be associated with a higher risk of subsequent neoplasms. Using this evidence, the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) has developed an evidence-based clinical practice guideline for the use of dexrazoxane in children with cancer expected to receive anthracyclines.3 Given the dose-dependent risk of anthracycline-induced cardiotoxicity, the guideline panel concluded that administration of dexrazoxane is reasonable in children who are expected to receive a cumulative doxorubicin or equivalent dose of at least 250 mg/m2 and that clinicians and patients/families should weigh the cardioprotective effect of dexrazoxane against the possible harms, including subsequent neoplasms. Unfortunately, no recommendation could be formulated for cumulative doxorubicin or equivalent doses of less than 250 mg/m2, due to insufficient evidence to determine whether the risk of cardiotoxicity outweighs the possible risk of subsequent neoplasms. For example, the recently updated IGHG recommendations for cardiomyopathy surveillance for survivors of childhood cancer even showed that patients treated with cumulative anthracycline doses of less than 100 mg/m2 were not at a significantly increased risk of heart failure or asymptomatic left ventricular dysfunction compared with those who received none, suggesting that use of dexrazoxane in patients planning to receive low-dose anthracyclines may be futile.4 Based on current evidence, dexrazoxane may be reasonable prior to every anthracycline dose in pediatric patients with additional risk factors for cardiac dysfunction, but does not apply to all pediatric patients treated with anthracyclines. We like to emphasize that the benefits of dexrazoxane probably outweigh the risk of subsequent neoplasms when the cumulative doxorubicin or equivalent dose is at least 250 mg/m2 and should be encouraged. Further research is encouraged to determine the long-term efficacy and safety of dexrazoxane in children with cancer, especially in children treated with cumulative doxorubicin or equivalent doses of lower than 250 mg/m2. Until then, the decision to use dexrazoxane in children with cancer should be guided by the available evidence to inform clinicians and patients alike. The authors declare no conflicts of interest.

Subjects

MeSH terms (MEDLINE)

DexrazoxaneNeoplasmsPolyketidesRazoxaneChildHumansAnthracyclinesAntibiotics, AntineoplasticCardiotonic AgentsCardiotoxicityConsensus Statements as Topic

Substances

AnthracyclinesAntibiotics, AntineoplasticCardiotonic AgentsDexrazoxanePolyketidesRazoxane

Authors and institutions

  • Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
  • Department of Pediatric Cardiology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, Netherlands.
  • Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
  • Population Sciences, City of Hope National Medical Center, Duarte, California, USA.

ORCID profiles: Annelies M C Mavinkurve-Groothuis, Esmee C de Baat, Elizabeth A M Feijen, Saro H Armenian

Cite

APA

Mavinkurve-Groothuis, A. M. C., de Baat, E. C., Feijen, E. A. M., Kremer, L. C. M., Armenian, S. H., Mulder, R. L., & van Dalen, E. C. (2023). Comment on: Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30604

Vancouver

Mavinkurve-Groothuis AMC, de Baat EC, Feijen EAM, Kremer LCM, Armenian SH, Mulder RL, et al. Comment on: Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30604

BibTeX
@article{MavinkurveGroothuis2023,
  author = {Mavinkurve-Groothuis, Annelies M C and de Baat, Esmee C and Feijen, Elizabeth A M and Kremer, Leontien C M and Armenian, Saro H and Mulder, Renee L and van Dalen, Elvira C},
  title = {Comment on: Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  doi = {10.1002/pbc.30604}
}
Start for free →